Advanced search
Publication Cover
Aging Health Volume 4, 2008 - Issue 1
Journal homepage
105
Views
0
CrossRef citations to date
0
Altmetric
Review

Alzheimer’s Disease and the Blood–Brain Barrier: Past, Present and Future

Gene L Bowman1 Oregon Health & Science University, CR-1313181 Southwest Sam Jackson Park Road, Portland, OR97239, USA Tel.: +1 503 494 6976; Fax: +1 503 494 7499; E-mail: [email protected]View further author information
&
Joseph F Quinn2 Oregon Health & Science University, Clinical Core, NIA-Layton Aging & Alzheimer’s Disease Center, ORUSA Tel.: +1 503 494 6976; Fax: +1 503 494 7499; E-mail: [email protected]View further author information
Pages 47-57 | Published online: 31 Jan 2008

Bibliography

  • Goldman E : Vitalfarburg am zentralnervensystem. Berlin: Eimer (1913).
  • Ehrlich P : Das Saurerstoff-Bedrurfnis des oraganismus: eine farbenanalytische studie. Berlin: Hirschward (1885).
  • Brightman MW : The distribution within the brain of ferritin injected into cerebrospinal fluid compartments. I. Ependymal distribution.J. Cell Biol.26, 99–123(1965).
  • Reese TS , KarnovskyMJ: Fine structural localization of a blood–brain barrier to exogenous peroxidase.J. Cell Biol.34, 207–217(1967).
  • Karnovsky MJ : The ultrastructural basis of capillary permeability studied with peroxidase as a tracer.J. Cell Biol.35, 213–236(1967).
  • Francis K , van Beek J, Canova C, Neal JW, Gasque P: Innate immunity and brain inflammation: the key role of complement. Expert Rev. Mol. Med.5, 1–19(2003).
  • Zlokovic BV : Neurovascular mechanisms of Alzheimer‘s neurodegeneration.Trends Neurosci.28, 202–208(2005).
  • Kroll RA , NeuweltEA: Outwitting the blood–brain barrier for therapeutic purposes: osmotic opening and other means.Neurosurgery42, 1083–1099; discussion 1099–1100 (1998).
  • Vera JC , RivasCI, FischbargJ, GoldeDW: Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid.Nature364, 79–82(1993).
  • Deane R , ZlokovicBV: Role of the blood–brain barrier in the pathogenesis of Alzheimer‘s disease.Curr. Alzheimer Res.4, 191–197(2007).
  • Deane R , Du Yan S, Submamaryan RK et al.: RAGE mediates amyloid-β peptide transport across the blood–brain barrier and accumulation in brain. Nat. Med.9, 907–913(2003).
  • Begley DJ , BrightmanMW: Structural and functional aspects of the blood–brain barrier.Prog. Drug Res.61, 39–78(2003).
  • Carmeliet P : Angiogenesis in health and disease.Nat. Med.9, 653–660(2003).
  • Deane R , WuZ, SagareAet al.: LRP/amyloid beta-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron43, 333–344(2004).
  • Shibata M , YamadaS, KumarSRet al.: Clearance of Alzheimer‘s amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier. J. Clin. Invest.106, 1489–1499(2000).
  • Frick E , Scheid-SeydelL: Exchange processes between plasma and cerebrospinal fluid examined with radio-iodine labeled albumin.Klin. Wochenschr.36, 66–69(1958).
  • Frick E , Scheid-SeydelL: Studies with γ globulin labeled with radioiodine on the origin of protein bodies in the cerebrospinal fluid.Klin. Wochenschr.36, 857–863(1958).
  • Cutler RW , DeuelRK, BarlowCF: Albumin exchange between plasma and cerebrospinal fluid.Arch. Neurol.17, 261–270(1967).
  • Tibbling G , LinkH, OhmanS: Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values.Scand. J. Clin. Lab. Invest.37, 385–390(1977).
  • Link H , TibblingG: Principles of albumin and IgG analyses in neurological disorders. II. Relation of the concentration of the proteins in serum and cerebrospinal fluid.Scand. J. Clin. Lab. Invest.37, 391–396(1977).
  • Kessler RM , GobleJC, BirdJHet al.: Measurement of blood–brain barrier permeability with positron emission tomography and (68 Ga) EDTA. J. Cereb. Blood Flow Metab.4, 323–328(1984).
  • Groothuis DR , VriesendorpFJ, KupferBet al.: Quantitative measurements of capillary transport in human brain tumors by computed tomography. Ann. Neurol.30, 581–588(1991).
  • Groothuis DR , LapinGD, VriesendorpFJ, MikhaelMA, PatlakCS: A method to quantitatively measure transcapillary transport of iodinated compounds in canine brain tumors with computed tomography.J. Cereb. Blood Flow Metab.11, 939–948(1991).
  • Ludemann L , HammB, ZimmerC: Pharmacokinetic analysis of glioma compartments with dynamic Gd-DTPA-enhanced magnetic resonance imaging.Magn. Reson. Imaging18, 1201–1214(2000).
  • Johnson G , WetzelSG, ChaS, BabbJ, Tofts PS: Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn. Reson. Med.51, 961–968(2004).
  • Alzheimer A : Uber eine eigenartige, Erkrankung der Hirnrinde.Allg. Z Psychiatrie64, 146–148(1907).
  • Glenner GG , WongCW: Alzheimer‘s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.Biochem. Biophys. Res. Commun.120, 885–890(1984).
  • Goldgaber D , LermanMI, McBrideOW, SaffiottiU, GajdusekDC: Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer‘s disease.Science235, 877–880(1987).
  • Kang J , LemaireHG, UnterbeckAet al.: The precursor of Alzheimer‘s disease amyloid A4 protein resembles a cell-surface receptor. Nature325, 733–736(1987).
  • Robakis NK , RamakrishnaN, WolfeG, WisniewskiHM: Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides.Proc. Natl Acad. Sci. USA84, 4190–4194(1987).
  • Tanzi RE , GusellaJF, WatkinsPCet al.: Amyloid β protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science235, 880–884(1987).
  • Selkoe DJ : Toward a comprehensive theory for Alzheimer‘s disease. Hypothesis: Alzheimer‘s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein.Ann. NY Acad. Sci.924, 17–25(2000).
  • Terry RD , MasliahE, SalmonDPet al.: Physical basis of cognitive alterations in Alzheimer‘s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol.30, 572–580(1991).
  • Lue LF , KuoYM, RoherAEet al.: Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer‘s disease. Am. J. Pathol.155, 853–862(1999).
  • McLean CA , ChernyRA, FraserFWet al.: Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer‘s disease. Ann. Neurol.46, 860–866(1999).
  • Naslund J , HaroutunianV, MohsRet al.: Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA283, 1571–1577(2000).
  • Hardy J , SelkoeDJ: The amyloid hypothesis of Alzheimer‘s disease: progress and problems on the road to therapeutics.Science297, 353–356(2002).
  • Silverberg GD , MayoM, SaulT, Rubenstein E, McGuire D: Alzheimer‘s disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol.2, 506–511(2003).
  • Tanzi RE , MoirRD, WagnerSL: Clearance of Alzheimer‘s Aβ peptide: the many roads to perdition.Neuron43, 605–608(2004).
  • Zlokovic BV : Clearing amyloid through the blood–brain barrier.J. Neurochem.89, 807–811(2004).
  • Alonzo NC , HymanBT, RebeckGW, GreenbergSM: Progression of cerebral amyloid angiopathy: accumulation of amyloid-β40 in affected vessels.J. Neuropathol. Exp. Neurol.57, 353–359(1998).
  • Greenberg SM , GurolME, RosandJ, Smith EE: Amyloid angiopathy-related vascular cognitive impairment. Stroke35, 2616–2619(2004).
  • Grammas P , YamadaM, ZlokovicB: The cerebromicrovasculature: a key player in the pathogenesis of Alzheimer‘s disease.J. Alzheimers Dis.4, 217–223(2002).
  • Snowdon DA , GreinerLH, MortimerJA, RileyKP, GreinerPA, MarkesberyWR: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study.JAMA277, 813–817(1997).
  • Vermeer SE , PrinsND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM: Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med.348, 1215–1222(2003).
  • Pluta R : Role of ischemic blood–brain barrier on amyloid plaques development in Alzheimer‘s disease brain.Curr. Neurovasc. Res.4, 121–129(2007).
  • Pluta R : Pathological opening of the blood–brain barrier to horseradish peroxidase and amyloid precursor protein following ischemia–reperfusion brain injury.Chemotherapy51, 223–226(2005).
  • Badan I , DincaI, BuchholdBet al.: Accelerated accumulation of N- and C-terminal β APP fragments and delayed recovery of microtubule-associated protein 1B expression following stroke in aged rats. Eur. J. Neurosci.19, 2270–2280(2004).
  • Gartshore G , PattersonJ, MacraeIM: Influence of ischemia and reperfusion on the course of brain tissue swelling and blood–brain barrier permeability in a rodent model of transient focal cerebral ischemia.Exp. Neurol.147, 353–360(1997).
  • Petito CK , PulsinelliWA, JacobsonG, Plum F: Edema and vascular permeability in cerebral ischemia: comparison between ischemic neuronal damage and infarction. J. Neuropathol. Exp. Neurol.41, 423–436(1982).
  • Ueno M , TomimotoH, AkiguchiI, Wakita H, Sakamoto H: blood–brain barrier disruption in white matter lesions in a rat model of chronic cerebral hypoperfusion. J. Cereb. Blood Flow Metab.22, 97–104(2002).
  • Wisniewski HM , WegielJ: Alzheimer‘s disease neuropathology. Current status of interpretation of lesion development.Ann. NY Acad. Sci.673, 270–284(1992).
  • Eikelenboom P , HackCE, KamphorstW, RozemullerJM: Distribution pattern and functional state of complement proteins and α1-antichymotrypsin in cerebral β/A4 deposits in Alzheimer‘s disease.Res. Immunol.143, 617–620(1992).
  • Wisniewski HM , VorbrodtAW, WegielJ: Amyloid angiopathy and blood–brain barrier changes in Alzheimer‘s disease.Ann. NY Acad. Sci.826, 161–172(1997).
  • Mann DM , DaviesJS, HawkesJ, YatesPO: Immunohistochemical staining of senile plaques.Neuropathol. Appl. Neurobiol.8, 55–61(1982).
  • Kalaria RN , GoldeTE, CohenML, YounkinSG: Serum amyloid P in Alzheimer‘s disease. Implications for dysfunction of the blood–brain barrier.Ann. NY Acad. Sci.640, 145–148(1991).
  • Claudio L : Ultrastructural features of the blood–brain barrier in biopsy tissue from Alzheimer‘s disease patients.Acta Neuropathol. (Berl.)91, 6–14(1996).
  • Stewart PA , HayakawaK, AkersMA, VintersHV: A morphometric study of the blood–brain barrier in Alzheimer‘s disease.Lab. Invest.67, 734–742(1992).
  • Alafuzoff I , AdolfssonR, BuchtG, Winblad B: Albumin and immunoglobulin in plasma and cerebrospinal fluid, and blood-cerebrospinal fluid barrier function in patients with dementia of Alzheimer type and multi-infarct dementia. J. Neurol. Sci.60, 465–472(1983).
  • Algotsson A , WinbladB: The integrity of the blood–brain barrier in Alzheimer‘s disease.Acta Neurol. Scand.115, 403–408(2007).
  • Blennow K , WallinA, ChongJK: Cerebrospinal fluid ‘neuronal thread protein’ comes from serum by passage over the blood–brain barrier.Neurodegeneration4, 187–193(1995).
  • Blennow K , WallinA, UhlemannC, GottfriesCG: White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors.Acta Neurol. Scand.83, 187–193(1991).
  • Elovaara I , PaloJ, ErkinjunttiT, SulkavaR: Serum and cerebrospinal fluid proteins and the blood–brain barrier in Alzheimer‘s disease and multi-infarct dementia.Eur. Neurol.26, 229–234(1987).
  • Skoog I , WallinA, FredmanPet al.: A population study on blood–brain barrier function in 85-year-olds: relation to Alzheimer‘s disease and vascular dementia. Neurology50, 966–971(1998).
  • Wada H : Blood–brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio.Intern. Med.37, 509–513(1998).
  • Frolich L , KornhuberJ, IhlR, FritzeJ, MaurerK, RiedererP: Integrity of the blood–CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG.Eur. Arch. Psychiatry Clin. Neurosci.240, 363–366(1991).
  • Kay AD , MayC, PapadopoulosNMet al.: CSF and serum concentrations of albumin and IgG in Alzheimer‘s disease. Neurobiol. Aging8, 21–25(1987).
  • Mecocci P , ParnettiL, ReboldiGPet al.: Blood–brain barrier in a geriatric population: barrier function in degenerative and vascular dementias. Acta Neurol. Scand.84, 210–213(1991).
  • Sun YX , MinthonL, WallmarkA, WarkentinS, BlennowK, JanciauskieneS: Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer‘s disease.Dement. Geriatr. Cogn. Disord.16, 136–144(2003).
  • Blennow K , WallinA, FredmanP, Gottfries CG, Karlsson I, Svennerholm L: Intrathecal synthesis of immunoglobulins in patients with Alzheimer‘s disease. Eur. Neuropsychopharmacol.1, 79–81(1990).
  • Bowman GL , KayeJA, MooreM, WaichunasD, CarlsonNE, QuinnJF: Blood–brain barrier impairment in Alzheimer disease: stability and functional significance.Neurology68, 1809–1814(2007).
  • Caserta MT , CaccioppoD, LapinGD, RaginA, GroothuisDR: Blood–brain barrier integrity in Alzheimer‘s disease patients and elderly control subjects.J. Neuropsychiatry Clin. Neurosci.10, 78–84(1998).
  • Dysken MW , NelsonMJ, HooverKM, KuskowskiM, McGeachieR: Rapid dynamic CT scanning in primary degenerative dementia and age-matched controls.Biol. Psychiatry28, 425–434(1990).
  • Schlageter NL , CarsonRE, RapoportSI: Examination of blood–brain barrier permeability in dementia of the Alzheimer type with [68Ga]EDTA and positron emission tomography.J. Cereb. Blood Flow Metab.7, 1–8(1987).
  • Wang H , GolobEJ, SuMY: Vascular volume and blood–brain barrier permeability measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with MCI and normal controls.J. Magn. Reson. Imaging24, 695–700(2006).
  • Starr JM , WardlawJ, FergusonK, MacLullichA, DearyIJ, MarshallI: Increased blood–brain barrier permeability in Type II diabetes demonstrated by gadolinium magnetic resonance imaging.J. Neurol. Neurosurg. Psychiatry74, 70–76(2003).
  • Bronge L , WahlundLO: White matter lesions in dementia: an MRI study on blood–brain barrier dysfunction.Dement. Geriatr. Cogn. Disord.11, 263–267(2000).
  • Hanyu H , AsanoT, TanakaY, IwamotoT, TakasakiM, AbeK: Increased blood–brain barrier permeability in white matter lesions of Binswanger‘s disease evaluated by contrast-enhanced MRI.Dement. Geriatr. Cogn. Disord.14, 1–6(2002).
  • Zlokovic BV , MartelCL, MatsubaraEet al.: Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid β at the blood–brain and blood–cerebrospinal fluid barriers. Proc. Natl Acad. Sci. USA93, 4229–4234(1996).
  • Selkoe DJ : Clearing the brain‘s amyloid cobwebs.Neuron32, 177–180(2001).
  • Martel CL , MackicJB, MatsubaraEet al.: Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood–brain barrier transport of circulating Alzheimer‘s amyloid β. J. Neurochem.69, 1995–2004(1997).
  • Leissring MA , FarrisW, ChangAYet al.: Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron40, 1087–1093(2003).
  • Kayed R , HeadE, ThompsonJLet al.: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science300, 486–489(2003).
  • Iwata N , HiguchiM, SaidoTC: Metabolism of amyloid-β peptide and Alzheimer‘s disease.Pharmacol. Ther.108, 129–148(2005).
  • Ghiso J , FrangioneB: Amyloidosis and Alzheimer‘s disease.Adv. Drug Deliv. Rev.54, 1539–1551(2002).
  • Kang DE , SaitohT, ChenXet al.: Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer‘s disease. Neurology49, 56–61(1997).
  • Hendriks L , van Duijn CM, Cras P et al.: Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nat. Genet.1, 218–221(1992).
  • Donahue JE , FlahertySL, JohansonCEet al.: RAGE, LRP-1, and amyloid-β protein in Alzheimer‘s disease. Acta Neuropathol.112, 405–415(2006).
  • Kislinger T , FuC, HuberBet al.: N(ε)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem.274, 31740–31749(1999).
  • Hori O , BrettJ, SlatteryTet al.: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem.270, 25752–25761(1995).
  • Hofmann MA , DruryS, FuCet al.: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell97, 889–901(1999).
  • Yan SD , ChenX, FuJet al.: RAGE and amyloid-β peptide neurotoxicity in Alzheimer‘s disease. Nature382, 685–691(1996).
  • Dickstein DL , BironKE, UjiieM, Pfeifer CG, Jeffries AR, Jefferies WA: Aβ peptide immunization restores blood–brain barrier integrity in Alzheimer disease. FASEB J.20, 426–433(2006).
  • Clarke R , SmithAD, JobstKA, RefsumH, SuttonL, UelandPM: Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease.Arch. Neurol.55, 1449–1455(1998).
  • Ravaglia G , FortiP, MaioliFet al.: Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am. J. Clin. Nutr.82, 636–643(2005).
  • Seshadri S , BeiserA, SelhubJet al.: Plasma homocysteine as a risk factor for dementia and Alzheimer‘s disease. N. Engl. J. Med.346, 476–483(2002).
  • Bostom AG , SilbershatzH, RosenbergIHet al.: Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch. Intern. Med.159, 1077–1080(1999).
  • Bots ML , LaunerLJ, LindemansJ, Hofman A, Grobbee DE: Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study. J. Intern. Med.242, 339–347(1997).
  • Malinow MR , NietoFJ, SzkloM, ChamblessLE, BondG: Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study.Circulation87, 1107–1113(1993).
  • Matsui T , AraiH, YuzurihaTet al.: Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people. Stroke32, 1116–1119(2001).
  • Perry IJ , RefsumH, MorrisRW, Ebrahim SB, Ueland PM, Shaper AG: Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet346, 1395–1398(1995).
  • Selhub J , JacquesPF, BostomAGet al.: Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med.332, 286–291(1995).
  • Lehmann M , ReglandB, BlennowK, GottfriesCG: Vitamin B12-B6-folate treatment improves blood–brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment.Dement. Geriatr. Cogn. Disord.16, 145–150(2003)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.